Some Sequences Will Not Stay in Solution

A purity figure describes the sample that reached the detector, not the contents of the vial. Anything that came out of solution before injection was taken out by the filter and never counted. That gap between the document and the material is one good reason to think about aggregation early, and the tendency is mostly written into the sequence — knowable before a solution is made rather than after it turns cloudy.

What the chromatogram can and cannot see

Soluble aggregates, where they survive to injection, tend to show up on a reversed-phase chromatogram as broad late-eluting peaks — or they stay on the column and never appear at all. Column chemistry covers what reversed-phase retention actually depends on.

Resolving oligomers as oligomers takes size-exclusion chromatography, which sorts by hydrodynamic size, and no standard identity package includes it. A further wrinkle arrives with cysteine: intermolecular bridging yields covalent dimers rather than merely associated ones, a case taken up in disulfide bonds.

The mechanism, and why it seems to start suddenly

Every dissolved peptide molecule is negotiating between two interactions: with solvent, and with other peptide molecules. Tip that balance toward peptide-peptide and association begins — small soluble oligomers at first, then larger assemblies, then visible particulate that either settles out or films the inside of the vial.

Nucleation explains the timing. A seed has to form before growth takes off, so a solution can sit apparently unchanged for hours and then deteriorate rapidly once one does.

Sequences that are predisposed

Non-polar residues prefer one another to water, so stretches built from valine, isoleucine, leucine or phenylalanine raise the tendency. Beta-sheet propensity pushes in the same direction: chains that can hydrogen-bond into extended sheets pack together with great efficiency, and what they build is stable and awkward to take apart again. Charge cuts the other way, since like charges repel and repulsion is what keeps molecules separated; a sequence with little net charge at its working pH has surrendered that protection, and the poorest solubility accordingly sits close to the isoelectric point. Length matters too, in the obvious direction: a short peptide offers less surface with which to associate.

Conditions that push it along

• Concentration. The dominant variable. Association needs several molecules at once, so the rate climbs steeply as they are brought closer. Make a stock up at maximum strength and it may aggregate where the very same material, diluted tenfold, does not.
• Agitation. More consequential than most people assume. Vortexing and shaking generate air-liquid interfaces; peptide adsorbs there and partially unfolds, and that seeds the next round of association. Swirling gently gets material into solution with far less of this than vigorous mixing does.
• Temperature. Ambiguous. For many sequences warmth improves solubility, and it speeds association at the same time, so warming a cloudy solution may clear it or may make things worse.
• Freeze-thaw. Not ambiguous at all. Ice formation concentrates whatever liquid is left behind, creating exactly the environment association needs.

Three habits follow. Make solutions up at whatever concentration the experiment genuinely calls for instead of the strongest the vial permits; dissolve gently; and hold it to the light before use. The solvent side of the decision is in choosing a reconstitution solvent, and keeping disturbance to a minimum is the subject of aliquoting and vial entry.

All material is supplied for laboratory research use only. It is not a drug, not a supplement, and not for use in humans or animals.